We found that knockdown of DCP2 in SCLC chemotherapy-sensitive cells significantly decreased the production of mitochondrial ROS (Fig. S6A) and significantly increased MMP (Fig. 7A-B), indicating that knockdown of DCP2 can reduce mitochondrial damage induced by chemotherapy drugs. Here, DCP2 is linked to small cell lung carcinoma.